# PHAR catalysts: Pharming Group N.V. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/phar/catalysts

> Pharming Group N.V. (PHAR) has 12 upcoming catalysts. The next is the Joenja® (leniolisib) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Pharming Group N.V. |
| Ticker | PHAR (Nasdaq) |
| SEC CIK | 1828316 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/phar |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [Joenja® (leniolisib) label expansion decision](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "The FDA approved Joenja for adults and pediatric patients aged 12 years and older with APDS in March 2023 and expanded the approval in September 2026 to include children aged 4 to 11 years weighing at least 27 kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm)) |
| March 24, 2023 | [Joenja® (leniolisib) FDA approval](https://sec-api.dev/pdufa/leniolisib) | PHAR | To treat activated phosphoinositide 3-kinase delta syndrome | completed, approved | "Joenja \| leniolisib \| 3/24/2023 \| To treat activated phosphoinositide 3-kinase delta syndromeDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| October 29, 2024 | [Joenja® (leniolisib) trial start](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "The first patient was dosed in the study on October 29, 2024 and enrollment is progressing." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm)) |
| December 11, 2024 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, positive | "On December 11, 2024, we announced positive top line results for the multinational Phase III clinical trial for children 4 to 11 years of age, which has been evaluating leniolisib tablets in 21 children with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000012/a2024q4pressrelease.htm)) |
| Mar 2025 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "In March 2025, we submitted an NDA for patients aged 12 years and older to the Ministry of Food and Drug Safety." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000015/pharm-20251231.htm)) |
| Mar 2025 | [Joenja® (leniolisib) FDA advisory committee meeting](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS in adult and adolescent patients 12 years of age and older | scheduled | "We received positive feedback from the Australian Advisory Committee on Medicines and in March 2025, we received approval for Joenja® (leniolisib) from the Australian TGA, for the treatment of APDS in adult and adolescent patients 12 years of age and older." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000017/pharm-20241231.htm)) |
| March 20, 2025 | [Joenja® (leniolisib) trial start](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000014/pharminggroupannouncesfirs.htm)) |
| Apr 2025 | [Napazimone trial start](https://sec-api.dev/pdufa/napazimone) | PHAR |  | completed | "We started the second wave of patient recruitment for the pivotal FALCON clinical trial in April 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000027/a2025q1pressrelease.htm)) |
| Jun 2025 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS in adult and pediatric patients 4 years of age and older | completed | "In June 2025, we submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for the approval of leniolisib for the treatment of APDS in adult and pediatric patients 4 years of age and older." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000034/a2025hy1pressrelease.htm)) |
| Q3 2025 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR | children aged 4 to 11 years diagnosed with APDS | scheduled | "We remain on track to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS in the third quarter of 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000034/a2025hy1pressrelease.htm)) |
| July 31, 2025 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR | children aged 4 to 11 years diagnosed with APDS | completed | "On July 31, 2025, we submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| October 1, 2025 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| January 30, 2026 | [Pharming Group N.V. complete response letter (CRL)](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | completed, complete response letter | "Following the Complete Response Letter (CRL) received on January 30, 2026, and a subsequent Type A meeting with the FDA on March 26, 2026, the resubmission seeks approval of 40 mg and 50 mg twice-daily dosing for pediatric patients weighing 27 kg or more, who represent a meaningful proportion of the identified pediatric patient population." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm)) |
| January 31, 2026 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "•PDUFA target action date of January 31, 2026" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000043/pharminggroupannouncesusfd.htm)) |
| January 31, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "On October 1, 2025, we announced that the FDA had accepted the sNDA and granted Priority Review of the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831625000049/a2025q3pressrelease.htm)) |
| February 1, 2026 | [Joenja® (leniolisib) complete response letter (CRL)](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, complete response letter | "Leiden, the Netherlands, February 1, 2026: Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to its supplemental New Drug Application (sNDA) for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000004/pharminggroupreceivescompl.htm)) |
| June 4, 2026 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR | children aged 4 to 11 years with APDS | completed | "On June 4, 2026, we announced that the U.S. Food and Drug Administration (FDA) had accepted our resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja as a treatment for children aged 4 to 11 years with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| June 23, 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | Primary Immunodeficiency Disorders (PIDs) | completed | "NCT06549114 (Leniolisib for Immune Dysregulation in PIDs): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06549114)) |
| July 30, 2026 | [Joenja® (leniolisib) NDA/BLA submission](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "On July 30, 2026, we submitted a separate sNDA seeking approval of lower Joenja doses for pediatric APDS patients aged 4 to 11 years who weigh 13 kg to 27 kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| August 12, 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | Common Variable Immunodeficiency (CVID) | completed | "NCT06897358 (Leniolisib for Immune Dysregulation in CVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897358)) |
| Aug to Nov 2026 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | Common Variable Immunodeficiency (CVID) | scheduled | "NCT06897358 (Leniolisib for Immune Dysregulation in CVID): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06897358)) |
| September 11, 2026 | [Joenja® (leniolisib) label expansion decision](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "On September 11, 2026, we announced that the U.S. Food and Drug Administration (FDA) had approved our supplemental New Drug Application (sNDA) for 40 mg and 50 mg twice-daily dosing of Joenja as a treatment for children aged 4 to 11 years weighing at least 27 kg with APDS." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| September 22, 2026 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | genetically defined primary immunodeficiencies | completed, positive | "Leiden, the Netherlands, September 22, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that a late-breaking abstract highlighting positive topline data from its Phase II trial with leniolisib in genetically identifiable primary immunodeficiencies (PIDs) with immune dysregulation linked to PI3Kd signaling has been accepted at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID), which will take place October 14-17, in the Netherlands." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000039/pharmingannouncespositivep.htm)) |
| September 25, 2026 | [Joenja® (leniolisib) NDA/BLA acceptance](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed | "Leiden, the Netherlands, September 25, 2026: Pharming (Euronext Amsterdam: PHARM/Nasdaq: PHAR), a global biotechnology company focused on rare immune and genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for lower doses of Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, for children aged 4 years and older who weigh between 13 kg and 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm)) |
| October 14, 2026 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, positive | "On October 14, 2026, we presented positive topline data from our Phase II trial of leniolisib in genetically identifiable PIDs with immune dysregulation at the 22nd Biennial Meeting of the European Society for Immunodeficiencies (ESID)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| October 24, 2026 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | completed, approved | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000033/a2026hy1pressrelease.htm)) |
| October 24, 2026 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000031/pharmingannouncesusfdaacce.htm)) |
| Nov 2026 to Feb 2027 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438407)) |
| November 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438407)) |
| January 30, 2027 | [Joenja® (leniolisib) PDUFA date](https://sec-api.dev/pdufa/leniolisib) | PHAR |  | scheduled | "On September 28, 2026, we announced that the FDA had accepted this sNDA and granted the application Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000049/a2026q3pressrelease.htm)) |
| January 30, 2027 | [Pharming Group N.V. PDUFA date](https://sec-api.dev/companies/phar/catalysts) | PHAR |  | scheduled | "•PDUFA target action date of January 30, 2027" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000041/pharmingannouncesusfdaacce.htm)) |
| late 2027 | [Napazimone topline data readout](https://sec-api.dev/pdufa/napazimone) | PHAR |  | scheduled | "We continue to expect Phase II read-outs for leniolisib in broader primary immunodeficiencies with immune dysregulation in the second half of 2026 and are on track to complete enrollment in the pivotal FALCON study of napazimone (KL1333) in 2026, with data readout anticipated in late 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1828316/000182831626000008/a2025q4pressrelease.htm)) |
| October 2027 | [KL1333 primary completion](https://sec-api.dev/pdufa/kl1333) | PHAR | Primary Mitochondrial Disease | scheduled | "NCT05650229 (Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05650229)) |
| Oct 2027 to Jan 2028 | [KL1333 topline data readout](https://sec-api.dev/pdufa/kl1333) | PHAR | Primary Mitochondrial Disease | scheduled | "NCT05650229 (Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05650229)) |
| Jul to Oct 2028 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05693129 (Pediatric Patients Aged 1 to 6 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-09 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05693129)) |
| July 2028 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05693129 (Pediatric Patients Aged 1 to 6 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-09 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05693129)) |
| Mar to Jun 2029 | [Napazimone topline data readout](https://sec-api.dev/pdufa/napazimone) | PHAR | Mitochondrial Diseases | scheduled | "NCT07514338 (Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07514338)) |
| March 2029 | [Napazimone primary completion](https://sec-api.dev/pdufa/napazimone) | PHAR | Mitochondrial Diseases | scheduled | "NCT07514338 (Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-03-31 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07514338)) |
| Aug to Nov 2029 | [Joenja® (leniolisib) topline data readout](https://sec-api.dev/pdufa/leniolisib) | PHAR | PIDs Linked to PI3K | scheduled | "NCT06990529 (Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-12 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990529)) |
| August 2029 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | PIDs Linked to PI3K | scheduled | "NCT06990529 (Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-12 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990529)) |

## Drugs

- [KL1333](https://sec-api.dev/pdufa/kl1333): Primary Mitochondrial Disease
- [Joenja® (leniolisib)](https://sec-api.dev/pdufa/leniolisib): apds in adult and pediatric patients 12 years of age and older in march 2023, children aged 4 to 11 years with apds, children aged 4 to 11 years diagnosed with apds, genetically defined primary immunodeficiencies, apds in adult and pediatric patients 4 years of age and older, and pediatric patients 12 years of age and older with apds, To treat activated phosphoinositide 3-kinase delta syndrome, APDS
- [Napazimone](https://sec-api.dev/pdufa/napazimone): Mitochondrial Diseases

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/phar/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PHAR catalysts: Pharming Group N.V. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/phar/catalysts

```bibtex
@misc{secapidev_companies_phar_catalysts_20261116,
  title        = {PHAR catalysts: Pharming Group N.V. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/phar/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_phar_catalysts_20261116","title":"PHAR catalysts: Pharming Group N.V. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/phar/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
